尿路上皮癌中抑制性受体对树突状细胞亚群的免疫调节
研究分析健康供者与尿路上皮癌(UCa)患者循环CD1c+树突状细胞(DC)、CD141+ DC和浆细胞样DC中PD-1、CTLA-4、BTLA、TIM-3和CD160的表达,发现不同DC亚群表达BTLA和TIM-3而不表达其他抑制性受体,且UCa患者血DC及膀胱肿瘤浸润DC的BTLA和TIM-3显著上调,配体介导的BTLA和TIM-3 engagement在体外显著降低DC亚群效应细胞因子分泌。
要点
- UCa患者血DC及肿瘤浸润DC的BTLA和TIM-3表达显著上调。
- 配体介导BTLA和TIM-3 engagement在体外显著降低DC效应细胞因子分泌。
- BTLA和TIM-3可能成为UCa治疗的潜在靶点。
核心结论
- UCa诱导DC局部和系统性过表达BTLA和TIM-3,可能导致其功能抑制,提示这些受体是UCa治疗的潜在靶点。
研究设计与样本
- 研究比较健康供者与尿路上皮癌患者循环CD1c+ DC、CD141+ DC和浆细胞样DC中PD-1、CTLA-4、BTLA、TIM-3和CD160的表达,并进行体外功能实验。
主要发现
- 不同DC亚群表达BTLA和TIM-3而不表达其他抑制性受体。
- UCa患者血DC中BTLA和TIM-3较健康供者显著上调。
- 膀胱肿瘤浸润DC较配对非肿瘤组织DC过表达BTLA和TIM-3。
- 配体介导的BTLA和TIM-3 engagement在体外显著降低DC亚群效应细胞因子分泌。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Blockade of inhibitory receptors (IRs) overexpressed by T cells can activate antitumor immune responses, resulting in the most promising therapeutic approaches, particularly in bladder cancer, currently able to extend patient survival. Thanks to their ability to cross-present antigens to T cells, dendritic cells (DCs) are an immune cell population that plays a central role in the generation of effective antitumor T-cell responses. While IR function and expression have been investigated in T cells, very few data are available for DCs. Therefore, we analyzed whether DCs express IRs that can decrease their functions. To this end, we investigated several IRs (PD-1, CTLA-4, BTLA, TIM-3, and CD160) in circulating CD1c+ DCs, CD141+ DCs, and plasmacytoid DCs from healthy donors and patients with urothelial cancer (UCa). Different DC subsets expressed BTLA and TIM-3 but not other IRs. More importantly, BTLA and TIM-3 were significantly upregulated in DCs from blood of UCa patients. Locally, bladder tumor-infiltrating DCs also overexpressed BTLA and TIM-3 compared to DCs from paired nontumoral tissue. Finally, in vitro functional experiments showed that ligand-mediated engagement of BTLA and TIM-3 receptors significantly reduced the secretion of effector cytokines by DC subpopulations. Our findings demonstrate that UCa induces local and systemic overexpression of BTLA and TIM-3 by DCs that may result in their functional inhibition, highlighting these receptors as potential targets for UCa treatment. PATIENT SUMMARY: We investigated the expression and function of a panel of inhibitory receptors in dendritic cells (DCs), an immune cell subpopulation critical in initiation of protective immune responses, among patients with urothelial carcinoma. We found high expression of BTLA and TIM-3 by blood and tumor DCs, which could potentially mediate decreased DC function. The results suggest that BTLA and TIM-3 might be new targets for urothelial carcinoma treatment.
引用
- Chevalier MF, Bohner P, Pieraerts C, et al. Immunoregulation of Dendritic Cell Subsets by Inhibitory Receptors in Urothelial Cancer. Eur Urol. 2016. PMID: 28277277. doi:10.1016/j.eururo.2016.10.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。